The goals of this study were two-fold: (1) to describe methods for drawing a population-based sample of individuals in care for HIV infection and (2) to compare data from the sample with data from existing surveillance systems that describe care for HIV.
Methods.
The authors implemented a two-stage sampling method, using local HIV/AIDS surveillance data as a sampling frame of HIV care providers in three states. At selected providers, medical records of a random sample of patients were abstracted.
Results.
The medical records of a number of patients, ranging from 253 to 374 individuals per state, were abstracted. The demographics of sampled individuals and of individuals reported to the local HIV/AIDS surveillance program were similar; however, differences existed in the proportion of individuals receiving HIV care consistent with treatment guidelines between the sample and a contemporary facility-based supplemental surveillance project. The median design effect for outcomes collected in the sample was 1.8 (range=0.5–29.6).
Conclusions.
This survey method is feasible for collecting population-based data on patients in care for HIV. Sample size and some design elements should be changed in future studies to increase precision of estimates and usefulness of data for local planning and evaluation.
References
1.
LeeLMKaronJMSelikRNealJJFlemingPL. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984–1997. JAMA2001;285:1308–15.
2.
Report of the NIH panel to define principles of therapy of HIV infection. MMWR Recomm Rep1998;47(RR-13):1–41.
ShapiroMFBerkMLBerrySHEmmonsCAAtheyLAHsiaDC. National probability samples in studies of low-prevalence diseases. Part I: Perspectives and lessons from the HIV cost and services utilization study. Health Serv Res1999;34 (5 Part 1):951–68.
5.
FrankelMRShapiroMFDuanNMortonSCBerrySHBrownJA. National probability samples in studies of low-prevalence diseases. Part II: designing and implementing the HIV cost and services utilization study sample. Health Serv Res1999;34(5 Part 1):969–92.
6.
FarizoKMBuehlerJWChamberlandMEWhyteBMFroelicherESHopkinsSG. Spectrum of disease in individuals with human immunodeficiency virus infection in the United States. JAMA1992;267:1798–805.
McNaghtenADHansonDLJonesDLDworkinMSWardJW. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. AIDS1999;13:1687–95.
Department of Health and Human Services (US), HIV/AIDS Bureau. Ryan White CARE Act [cited 2005 Jan 15]. Available from: URL: http://hab/hrsa.gov/history.htm
11.
Insightful Corporation. S-PLUS: Version 6. Washington: Insightful Corporation; 2003.
12.
SAS Institute. SAS: Version 8.2. Cary (NC): SAS Institute; 2002.
13.
Research Triangle Institute. SUDAAN user manual, release 8.0. Research Triangle Park (NC): Research Triangle Institute; 2001.
14.
CochranWG. Sampling techniques. New York: John Wiley & Sons; 1977.
15.
MooreRDStantonDGopalanRChiassonRE. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med1994;330:763–8.
16.
HsuLCVittinghoffEKatzMHSchwarczSK. Predictors of use of highly active antiretroviral therapy (HAART) among individuals with AIDS in San Francisco, 1996–1999. J Acquir Immune Defic Syndr2001;28:345–50.
17.
KlevensRMFlemingPLLiJGainesCGGallagherKSchwarczK. The completeness, validity, and timeliness of AIDS surveillance data. Ann Epidemiol2001;11:443–9.
18.
United States Public Health Service and Infectious Disease Society of America. USPHS/IDSA guidelines for the prevention of opportunistic infections in individuals infected with human immunodeficiency virus [cited 2005 Jan 15]. Available from: URL: http://aidsinfo.nih.gov/guidelines/default_db2.asp?id=69
19.
1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep1992;41 (RR-17):1–19.
20.
KaplanJEHansonDLJonesJL. Early initiation of combination antiretroviral therapy: does it affect clinical outcome?Proceeding of the 13th International AIDS Conference; 2000 July; Durban, South Africa. Abstract No.: LbPeB7051.
21.
DworkinMSHansonDLKaplanJEJonesJLWardJW. Risk for preventable opportunistic infections in individuals with AIDS after antiretroviral therapy increases CD4 + T lymphocyte counts above prophylaxis thresholds. J Infect Dis2000;182:611–5.
22.
KaplanJEHansonJLNavinTRJonesJL. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. J Infect Dis1998;178:1126–32.
23.
BrooksJT. Risk of Mycobacterium avium complex (MAC) infection among HIV-infected individuals who stop primary prophylaxis after HAART-associated immune reconstitution. Proceedings of the Infectious Diseases Society of America 40th Annual Meeting; 2000; San Diego (CA). Abstract No.: 500.
24.
BlairJHansonDLJonesJL. Do gender differences in viral load predict differences in HIV disease progression?Proceedings of the 7th Conference on Retroviruses and Opportunistic Infections; 2000 Feb; San Francisco. Abstract No.: 195.
25.
BozzetteSABerrySHDuanNFrankelMRLeibowitzAALefkowitzD. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med1998;339:1897–904.
26.
NakashimaAKFlemingPL. HIV/AIDS surveillance in the United States, 1981–2001. J Acquir Immune Defic Syndr2003;32Suppl 1:S68–S85.
27.
Centers for Disease Control and Prevention. HIV prevention strategic plan through 2005 [cited 2005 Jan 15]. Available from: URL: www.cdc.gov/nchstp/od/hiv_plan
28.
HansenMHHurwitzWNMadowWG. Sample survey methods and theory. New York: John Wiley & Sons; 1953.
29.
KishL. Survey sampling. New York: John Wiley; 1965.
